Bayesian inference for a principal stratum estimand on recurrent events truncated by death

Recurrent events are often important endpoints in randomized clinical trials. For example, the number of recurrent disease‐related hospitalizations may be considered as a clinically meaningful endpoint in cardiovascular studies. In some settings, the recurrent event process may be terminated by an e...

Full description

Saved in:
Bibliographic Details
Published inBiometrics Vol. 79; no. 4; pp. 3792 - 3802
Main Authors Lyu, Tianmeng, Bornkamp, Björn, Mueller‐Velten, Guenther, Schmidli, Heinz
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.12.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Recurrent events are often important endpoints in randomized clinical trials. For example, the number of recurrent disease‐related hospitalizations may be considered as a clinically meaningful endpoint in cardiovascular studies. In some settings, the recurrent event process may be terminated by an event such as death, which makes it more challenging to define and estimate a causal treatment effect on recurrent event endpoints. In this paper, we focus on the principal stratum estimand, where the treatment effect of interest on recurrent events is defined among subjects who would be alive regardless of the assigned treatment. For the estimation of the principal stratum effect in randomized clinical trials, we propose a Bayesian approach based on a joint model of the recurrent event and death processes with a frailty term accounting for within‐subject correlation. We also present Bayesian posterior predictive check procedures for assessing the model fit. The proposed approaches are demonstrated in the randomized Phase III chronic heart failure trial PARAGON‐HF (NCT01920711).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0006-341X
1541-0420
1541-0420
DOI:10.1111/biom.13831